On 12 October 2026, Hong Kong–listed Sisram Medical (stock code 01696) repurchased 99,200 ordinary shares on the Stock Exchange under its existing general mandate approved on 24 June 2026. The shares were bought at prices ranging from HKD 1.98 to HKD 2.00, with a volume-weighted average cost of HKD 1.9978 per share, bringing total consideration to approximately HKD 0.20 million.

Following the transaction, Sisram Medical’s outstanding share count (excluding treasury shares) declined by 0.02 % to 468.22 million shares. Treasury shares increased from 20,000 to 119,200, while the company’s total issued share capital remained unchanged at 468.34 million shares.

The latest purchase brings cumulative buybacks under the 46.83 million-share mandate to 119,200 shares, equivalent to 0.03 % of the authorised limit and 0.025 % of the company’s issued shares on the mandate date. In line with Hong Kong Stock Exchange requirements, Sisram Medical is restricted from issuing new shares or selling treasury shares until 11 November 2026, 30 days after the repurchase date.